Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Trisha Parks

Obstetrics & Gynecology Tulsa, OK Doctor of Osteopathy

NPI 1003902768 CMS profile 136364

5010 E 68Th St Ste 200, Tulsa, OK 74136

Open in the dashboard

General payments

$7,286

439 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Trisha Parks of Tulsa, OK is reported in the CMS Open Payments database as having received $7,286 across 439 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,006 70
2024 General $984 45
2023 General $1,212 69
2022 General $1,326 87
2021 General $1,868 112
2020 General $522 34
2019 General $369 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trisha Parks
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Trisha Parks were reported at $1,006. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Trisha Parks Obstetrics & Gynecology median Middle half National median
2019 $369 $172 $62–$391 $163
2020 $522 $94 $36–$222 $114
2021 $1,868 $136 $42–$369 $132
2022 $1,326 $160 $50–$433 $149
2023 $1,212 $169 $56–$423 $160
2024 $984 $152 $50–$371 $164
2025 $1,006 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,910 112 payments
  2. Mayne Pharma Inc. $851 64 payments
  3. Novo Nordisk Inc $570 43 payments
  4. Agile Therapeutics, Inc. $439 21 payments
  5. Astellas Pharma US Inc $365 18 payments
  6. Exeltis, USA Inc. $352 18 payments
  7. TherapeuticsMD, Inc. $329 24 payments
  8. Sumitomo Pharma America, Inc. $267 14 payments
  9. Millicent US Inc $239 13 payments
  10. Currax Pharmaceuticals LLC $221 16 payments
  11. Other $1,743 96 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,256 437 payments
  2. Education $30 2 payments
Products named General payments · program years 2019–2025
  1. LO LOESTRIN FE $1,099 65 payments
  2. ORILISSA $518 31 payments
  3. Twirla $439 21 payments
  4. Veozah $365 18 payments
  5. NEXTSTELLIS $345 15 payments
  6. UBRELVY $306 19 payments
  7. ORIAHNN $281 17 payments
  8. LILETTA $267 14 payments
  9. MYFEMBREE $246 13 payments
  10. Saxenda $244 20 payments
  11. Other $3,875 235 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

48

Median for Obstetrics & Gynecology: 65

Drug cost

$1,774

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

0%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 15 $1,048
Fluoxetine Hcl Generic 15 $473
Escitalopram Oxalate Generic 18 $254

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $194
$194 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $161
$161 — —
NEXTSTELLIS
  • Mayne Pharma Inc. $125
$125 — —
SLYND
  • Exeltis, USA Inc. $44
$44 — —
INTRAROSA
  • MILLICENT US INC $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

439 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record